Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vericel Corporation - Common Stock (NQ:VCEL)

45.96 -1.65 (-3.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vericel Corporation - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Vericel Q2 Earnings Call Highlights ↗
Vericel (NASDAQ:VCEL) reported record second-quarter revenue and raised its full-year outlook, citing continued growth in its MACI cartilage repair franchise and Burn Care business, along with improved... 
Via MarketBeat
Topics Earnings
Vericel (NASDAQ:VCEL) Beats Q2 Estimates, Raises Guidance, Shares Rise ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Strong Growth Stock With a Bull Flag Breakout Setup ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): An Affordable Growth Stock at a Reasonable Valuation ↗
Via Chartmill
News headline image
Vericel Stock Is Up 10%. Here's What This $402,000 Insider Sale Really Suggests ↗
Focused on regenerative therapies for sports medicine and burn care, this biopharma firm reported a notable insider sale in June. 
Via The Motley Fool
Topics Regulatory Compliance
Vericel Corp (NASDAQ:VCEL): A Classic Affordable Growth Stock in Biotech ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): Growth and Technical Setup Align for Potential Breakout ↗
Via Chartmill
Vericel (NASDAQ:VCEL) Balances High Growth and Reasonable Valuation in Affordable Growth Screen ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL): A Prime Example of Affordable Growth ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Smashes Q1 Estimates, Raises Full-Year Outlook as MACI and Burn Care Surge ↗
Via Chartmill
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Vericel develops cell therapies for cartilage repair and burn care, serving hospitals and clinics across the United States. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
MediWound (MDWD) Q1 2026 Earnings Transcript ↗
MediWound (MDWD) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Vericel Q1 Earnings Call Highlights ↗
Vericel (NASDAQ:VCEL) reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as... 
Via MarketBeat
Topics Earnings
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup Opportunity ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Emerges as a Top Affordable Growth Pick ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Breakout Case ↗
Via Chartmill
News headline image
Vericel (VCEL) Q1 2026 Earnings Transcript ↗
Vericel (VCEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Vericel (VCEL) Q4 2025 Earnings Call Transcript ↗
Vericel (VCEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Vericel Corp (NASDAQ:VCEL) Reports Q4 2025 Earnings In Line, Beats on Profitability ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Presents a Strong Growth and Breakout Setup ↗
Via Chartmill
Vericel Corp (NASDAQ:VCEL) Emerges as a Prime GARP Investment Candidate ↗
Via Chartmill
VERICEL CORP (NASDAQ:VCEL) Fits the "Growth at a Reasonable Price" Profile ↗
Via Chartmill
News headline image
Why Is Vericel Stock Gaining Tuesday? ↗
Vericel Corporation (NASDAQ: VCEL) stock rose on Tuesday after announcing preliminary financial results for 2025. 
Via Benzinga
News headline image
Vericel Corp. (NASDAQ:VCEL) Presents a High-Growth Profile with a Technical Setup for a Potential Breakout ↗
Vericel Corp. (VCEL) combines strong revenue growth and accelerating earnings with a technical setup suggesting a potential price breakout from a key support level. 
Via Chartmill
News headline image
Vericel Corp (NASDAQ:VCEL) Emerges as a Top GARP Investment Candidate ↗
Vericel Corp (VCEL) exemplifies GARP investing with strong growth, high profitability, and a valuation reasonable for its biotech sector. 
Via Chartmill
News headline image
Vericel Corp (NASDAQ:VCEL) Emerges as a Top Affordable Growth Candidate ↗
Vericel (VCEL) offers affordable growth in biotech with strong revenue & earnings, solid financials, and a reasonable valuation relative to peers. 
Via Chartmill
News headline image
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings ↗
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel (VCEL) Q3 2025 Earnings Call Transcript ↗
Vericel (VCEL) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vericel Corporation (NASDAQ:VCEL) Surpasses Earnings Estimates with Strong Q3 2025 Results ↗
Vericel (VCEL) beats Q3 2025 earnings estimates with strong revenue growth and a swing to profitability, driven by its MACI and burn care products. 
Via Chartmill
News headline image
Vericel Corp (NASDAQ:VCEL) Presents a Compelling Growth and Technical Setup ↗
Vericel (VCEL) combines strong revenue & earnings growth with a bullish technical setup, making it a top biotech growth stock to watch. 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.